Introduction
Methods
Search Strategy
Study Selection
Quality Assessment
Data Synthesis
Author/year/UK region | Research topic | Research design | Data analysis, data collection and sampling method | Healthcare setting | Age range (years) | Ethnicity | Male to female ratio |
---|---|---|---|---|---|---|---|
Lawton et al. 2005 [32] Scotland | Perception and experience of OGLD | Cross-sectional | Grounded theory In-depth interviews Purposive/snowballing | PC/community | 30 to ≥ 71 | Pakistani/Indian | 15:17 |
Lawton et al. Parry et al. 2006 [35] Scotland | Perception of T2DM, issues of cause and control, perception and experience of OGLD | Longitudinal | Grounded theory Field notes Repeat semi-structured interviews × 4 per participant (first 3 in year 1 (baseline), 6 months, 12 months and 4th in year 3) Purposive | PC/SC | Rounds 1–3: 21–71 plus Round 4: 40–80 | 39 Caucasians 1 Pakistani | Rounds 1–3: 22:18 Round 4: 11:9 |
Morris et al. 2005 [36] North West England | Insulin initiation | Longitudinal | Interpretive phenomenology Participant observation notes/repeat interviews (2 weeks after insulin initiation and then 1 month after) Purposive | SC | 59–73 | 1 Asian 1 African–Caribbean 4 Caucasian | 3:3 |
Phillips 2007 [37] West Midlands | Insulin initiation | Cross-sectional | Phenomenology In-depth interviews/Field notes Purposive | SC | Women: 59–72 Men: 49–72 | NS | 4:4 |
Khan et al. 2008 [38] London | Reasons for insulin refusal | Cross-sectional | Focus groups (single -sex groups) Purposive | SC | NSb | Bangladeshi | 20:16 |
Noakes 2010 [39] London | Perception of insulin therapy | Cross-sectional | Focus groups (tablet and insulin groups) Purposive | SC | 44–77 (tablet group) 53–69 (insulin group) | 5 Black-Africans 8 African–Caribbeans | 2:5 (tablet group) 3:3 (insulin group) |
Jenkins et al. Nationwide | Insulin initiation and intensification | Cross-sectional | Grounded theory In depth interviews Purposive | SC-clinical trial centers | Mean 64.7 ± 8.5 | Majority White British | 29:16 |
Brod et al. 2014 [42] London (multi-national study) | Barriers to insulin initiation | Cross-sectional | Modified grounded Theory Focus groups (per country; 2 in UK) Purposive | NSa | NSa | NS | NS (n = 15 in UK) |
Patel et al. 2015 [43] East Midlands | Concerns and perception of insulin therapy | Cross-sectional | Grounded theory Semi-structured interviews Purposive | PC | NS | 13 South Asian, mainly Indian origin 5 Caucasians | 9:9 |
Bissell et al. 2004 [44] North West England | Views and experience of T2DM treatment from compliance to concordance | Cross-sectional | Grounded theory Face-to-face interviews Purposive/snowballing | PC/SC/community | Pakistani origin | NS (n = 21) | |
Stone et al. 2005 [45] East Midlands | Experience and attitude of T2DM and its treatment | Cross-sectional | Semi-structured interviews (multiple interviewers) Purposive | PC | 37–80 (South Asians) | 15 South Asians, Indian origin 1 Caucasian | NS (n = 19) |
Brown et al. 2007 [46] East Midlands | Health beliefs of T2DM | Cross-sectional | Face-to-face interviews Theoretical sampling | PC/community | 40–76 | African Caribbean | 6:10 |
Vermeire et al. 2007 [47] NS (multi-national study) | Obstacles to adherence in living with T2DM | Cross-sectional | Grounded theory- individual focus groups; then meta-ethnography all groups Focus groups (per country; 5 in UK) sampling NS | NS | < 50–75 | NS | 9:10 (from UK) |
Hood et al. 2009 [48] London | Experience of T2DM | Cross-sectional | In-depth semi-structure interviews (2 per participant) Purposive | SC (some participants managed in PC) | Mean 70 | White British | 19:9 |
Stack et al. 2008 [49] NS | Multiple medicines beliefs | Cross-sectional | Modified grounded Theory Semi-structured interviews Purposive | PC | 41–82 | 4 African–Caribbean 3 South Asian 11 White British 1 White-European | 9:10 |
Bower et al. 2012 [50] North West England | Illness representations with multi-morbid conditions | Cross-sectional | Semi-structured interviews Purposive | PC | 39–89 | NS | NS (n = 23) |
Author/year/UK region | Duration of diabetes (years) | HbA1c (% [mmol/mol]) Weight (kg) BMI (kg/m2) | T2DM complications present (yes/no) | T2DM medicine regime and/or type (n) | Medicine-taking duration (years) | Theoretical model |
---|---|---|---|---|---|---|
Lawton et al. 2005 [32] Scotland | 0 to ≥ 16 | NS | NS | 4 Sulphonylurea 12 Metformin 13 Sulphonylurea and metformin 3 Diet only | NS | NS |
Lawton et al. Parry et al. 2006 [35] Scotland | ≤ 0.5 | NS | NS | Interview 1: 9 diet only, 11 OGLD monotherapy, 0 OGLD combination therapy, 0 insulin and OGLDs Interview 4: 6 diet only, 5 OGLD monotherapy (3 increased dose), 8 OGLD combination therapy, 1 insulin and OGLDs mentioned(metformin/gliclazide) | 0.5–3 depending on interview round | NS-key findings related to: “Contextual Knowing” [51] |
Morris et al. 2005 [36] North West England | 6–31 | NS | Yes | BD injections of biphasic insulin All participants experienced OGLDs | Insulin 1 month OGLD NS | NS |
Phillips 2007 [37] West Midlands | NS | NS | NS | Women: 4 BD insulin Men: 3 BD insulin, 1 OD insulin | Insulin 2–4 OGLD NS | NS |
Khan et al. 2008 [38] London | NSb | HbA1c: 8–13.8 [64–127] weight/BMI: NS | Yes | NS; inclusion criteria indicate that they should be on maximum oral therapy (i.e. metformin, sulphonylurea and glitazone) where not contraindicated All refused insulin initiation | OGLD NS | Psychological insulin resistance [54] but does not link it with study data |
Noakes 2010 [39] London | 0.3–11 (tablet group) 4–26 (insulin group) | NS | NS | Taking OGLDs and/or insulin | 0.3–10 (tablet group) 0.4–22 (insulin group) | Psychological insulin resistance [54] but does not link it with study data |
Jenkins et al. Nationwide | NS | HbA1 cc: 5.3–9.9 [34–85] 26 participants ≤ 7 [53] 19 participants ≤ 6.5 [48] Weight/BMI: BMI ≤ 40 Weight gain: Biphasic group mean 5.7 ± 0.5 Prandial group: mean 6.4 ± 0.5 Basal group: mean 3.6 ± 0.5 | NS | Insulin initiation: Arm 1: 15 basal insulin (OD) Arm 2: 15 biphasic Insulin (BD) Arm 3: 15 prandial insulin (TDS) Metformin and/or Sulphonylurea Insulin Intensification (n = 41 at year 2/3 of trial) Arm 1: basal and prandial Arm 2: 13 biphasic and prandial Arm 3: 14 prandial and basal On metformin if tolerated, sulphonylurea discontinued | Insulin > 2d OGLD NS | Psychological insulin receptiveness [40] |
Brod et al. 2014 [42] London (multi-national study) | NS | NS | NS | Equal mix initiated/refused insulin All taking OGLDs | OGLD NS Insulin for those initiated: < 0.5 | |
Patel et al. 2015 [43] East Midlands | < 10 to > 20 years | NS | NS | 7 insulin 11 not on insulin (two on OGLDs, no details given for others) | NS (2 participants were taking insulin for > 2 years, no details given for the others | |
Bissell et al. 2004 [44] North West England | NS | NS | NS | Participants’ quotes about metformin | NS | Biographical model of care [59] with a link to concordance |
Stone et al. 2005 [45] East Midlands | < 1–35 (South Asian) | NS | NS | 1 diet only 13 OGLD 2 insulin | NS | NS |
Brown et al. 2007 [46] East Midlands | 0.3–29 | NS | Yes | 5 diet only 6 insulin 5 OGLDs | NS | NS |
Vermeire et al. 2007 [47] NS (multi-national study) | 1–22 | NS | NS | Mentioned insulin | NS | NS in order to facilitate direct comparison between focus groups |
Hood et al. 2009 [48] London | > 20 | NS | Yes | 23 insulin 5 OGLDs (1 about to commence insulin, 2 stopped insulin due to weight loss) | NS | Chronic illness as a biographical disruption [60] |
Stack et al. 2008 [49] NS | NS | NS | NS | Number of medicines prescribed for whole group: 24 OGLDs 5 insulin Mentioned metformin, gliclazide, pioglitazone | NS | NS—commented about strategic compliance; does not link with study data. |
Bower et al. 2012 [50] North West England | NS | NS | NS | NS (various medicines for multimorbidity) | NS |